PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Axitinib Pharmacokinetics in Chinese Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AG-013736 (axitinib)
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2009-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00919204
- Locations
- 🇨🇳
Pfizer Investigational Site, Beijng, China
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
- Conditions
- Pneumococcal Conjugate Vaccine
- Interventions
- Biological: 13-valent Pneumoccocal Conjugate Vaccine
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 158
- Registration Number
- NCT00918580
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00918476
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Food Effect Study Of AG-013736 In Healthy Volunteers
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2009-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00918632
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00918164
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 62
- Registration Number
- NCT00916617
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Pharmacology Research Institute, Encino, California, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
- Conditions
- Advanced Non-Hematologic Malignancies
- Interventions
- Drug: PF-04605412
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT00915278
- Locations
- 🇬🇧
Pfizer Investigational Site, Sutton, Surrey, United Kingdom
Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
- Conditions
- Hemophilia A
- Interventions
- Biological: Moroctocog alfa ( AF-CC)Procedure: Laboratory tests
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00914459
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇬🇪LTD Medinvesti- Institute of hematology and transfusiology, Tbilisi, Georgia
🇮🇹Centro di Riferimento Regionale per la cura dell'Emofilia e delle Malattie Emorragiche Congenite, Parma, Italy
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00914667
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
- Conditions
- Thrombosis
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00914641
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States